Oct 16, 2017 - Health

Shorter antibiotic regime appears effective for drug-resistant TB

Shane Savitsky

An Indian doctor examines a X-ray picture of a tuberculosis patient. Photo: Channi Anand / AP

A shorter nine-month course of antibiotics might be just as effective in fighting multi-drug-resistant tuberculosis (MDR TB) as the current two-year standard, according to early results from an international clinical trial, per the New York Times. The trial saw a 78% success rate, compared with 81% for the two-year treatment.

Why it matters: Each year, nearly 500,000 people become sick with MDR TB, leading to about 200,000 deaths, according to the Centers for Disease Control and Prevention. A shorter medication regime would benefit the infected populace, which is centered in the developing world.

Current treatments: "Patients with even uncomplicated tuberculosis must take four drugs a day for six months. Treating drug-resistant tuberculosis can require in-hospital intravenous infusions and toxic second-line antibiotics that may cause nausea, deafness, liver damage and other side effects that lead patients to drop out of treatment," the NYT piece stated.

Limitations: Trials tend to show a higher rate of success than real-life scenarios, likely due to the increased scrutiny given during the trials, the researchers said.

"Unlike drug-sensitive TB, which can be treated effectively and cured with the current standard of care, treatment outcomes for MDR-TB are poor, with less than half of cases having successful outcomes with no more than one in 10 MDR-TB patients being effectively identified and treated," according to the study, conducted by the International Union Against Tuberculosis and Lung Disease and UCL.

Add Axios on Google

Shorter antibiotic regime appears effective for drug-resistant TB

What to read next